OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is...
Dec 4, 2025, 3:19 PM EST - 1 hour ago
Dec 2, 2025, 9:53 AM EST - 2 days ago
Dec 1, 2025, 3:01 PM EST - 3 days ago
Nov 21, 2025, 9:20 AM EST - 13 days ago
Nov 14, 2025, 11:10 AM EST - 20 days ago
Nov 6, 2025, 8:30 AM EST - 4 weeks ago
Oct 20, 2025, 11:39 AM EDT - 6 weeks ago
Oct 14, 2025, 8:30 AM EDT - 7 weeks ago
Sep 9, 2025, 5:30 PM EDT - 3 months ago
Aug 1, 2025, 1:29 PM EDT - 4 months ago
Jul 31, 2025, 12:45 PM EDT - 4 months ago
Jul 30, 2025, 4:10 PM EDT - 4 months ago
Jul 24, 2025, 7:30 AM EDT - 4 months ago
Jul 15, 2025, 7:30 AM EDT - 5 months ago
Jul 9, 2025, 7:58 AM EDT - 5 months ago
May 22, 2025, 7:36 AM EDT - 7 months ago
May 2, 2025, 7:30 AM EDT - 7 months ago
Apr 9, 2025, 7:54 AM EDT - 8 months ago
Apr 3, 2025, 7:30 AM EDT - 8 months ago
Mar 26, 2025, 7:16 AM EDT - 9 months ago
Mar 25, 2025, 7:00 AM EDT - 9 months ago
Feb 14, 2025, 6:10 PM EST - 10 months ago